Extended post-discharge thromboprophylaxis in hospitalized COVID-19 patients.
Expert Rev Hematol
; 15(7): 597-605, 2022 07.
Статья
в английский
| MEDLINE | ID: covidwho-1915459
ABSTRACT
INTRODUCTION:
Hospitalized COVID-19 patients, particularly those with high-risk features, are at risk for venous and arterial thromboembolic events for approximately 30 days or more after hospital discharge. Extended post-hospital discharge thromboprophylaxis has potential to reduce this risk. AREAS COVERED Recent cohort, registry, and randomized trial data on the topic of extended post-discharge thromboprophylaxis in COVID-19 inpatients are reviewed, and key patient subgroups at high thrombotic risk are highlighted, with antithrombotic guidelines on the topic discussed. EXPERT OPINION COVID-19 inpatients with cardiovascular risk factors, advanced age, intensive care unit stay, or an IMPROVE VTE score of 4 or more or a score of 2 or 3 plus elevated D-dimers (> twice the upper limit of normal) or an IMPROVE-DD VTE score of ≥4 are at high thrombotic risk in the post-discharge period. These high-risk patient subgroups benefit from extended post-discharge thromboprophylaxis, specifically with rivaroxaban 10 mg daily for 35 days. Recent NIH and ISTH guidelines recommend or suggest this approach. Results from other clinical trials are pending.ключевые слова
Полный текст:
Имеется в наличии
Коллекция:
Международные базы данных
база данных:
MEDLINE
Основная тема:
Venous Thromboembolism
/
COVID-19
Тип исследования:
Когортное исследование
/
Экспериментальные исследования
/
Наблюдательное исследование
/
Прогностическое исследование
/
Рандомизированные контролируемые испытания
Темы:
Длинный Ковид
Пределы темы:
Люди
Язык:
английский
Журнал:
Expert Rev Hematol
Тематика журнала:
Гематология
Год:
2022
Тип:
Статья
Аффилированная страна:
17474086.2022.2098104
Документы, близкие по теме
MEDLINE
...
LILACS
LIS